舒洛地特治疗糖尿病肾病合并视网膜病变对血清VEGF、ACE、IGF-1水平的影响观察
|
摘要
目的探究舒洛地特治疗糖尿病肾病(DN)合并视网膜病变(DR)对血清血管内皮生长因子(VEGF)、血管紧张素转化酶(ACE)、胰岛素样生长因子-1(IGF-1)水平的影响。方法采用随机数字表法将72例DN合并DR患者分为研究组和对照组各36例。对照组患者予以前列地尔+厄贝沙坦+欧洲越桔花青苷/β-胡萝卜素治疗,研究组患者予以舒洛地特序贯疗法。比较两组患者DR疗效,观察治疗前后尿白蛋白排泄率(UAER)及血清VEGF、ACE、IGF-1水平变化情况。结果两组患者DR疗效比较差异无统计学意义(P﹥0.05);治疗16周后,两组患者UAER及血清VEGF、ACE、IGF-1水平均较治疗前降低,且研究组低于对照组(P﹤0.05)。结论舒洛地特能有效缓解DN合并DR患者的眼底病变,促进肾功能恢复,通过降低血清VEGF、ACE、IGF-1各因子表达延缓疾病进展。
Objective To explore the effect of sulodexide on serumvascular endothelial growth factor(VEGF), angiotensin converting enzyme(ACE) and insulin-like growth factor-1(IGF-1)levels in patients with diabetic nephropathy(DN)and diabetic retinopathy(DR). Methods 72 patients with DN and DR were randomly divided into study group(36 cases) and control group(36 cases). The control was given alprostadil, irbesartan and European bilberry anthocyanin/beta carotene, while the study group was given sequential therapy with sulodexide. The curative effects of DR in the two groups were compared, and the changes of urinary albumin excretion rate(UAER), serum VEGF, ACE and IGF-1 levels were observed before and after treatment. Results There was no significant difference in the curative effects of DR between the two groups(P>0.05). 16 weeks after treatment, the levels of UAER, VEGF, ACE and IGF-1 in the two groups were all significantly decreased, and the decrease in the study group was greater than that in the control group(P<0.05). Conclusion Sulodexide can effectively alleviate the fundus lesions in patients with DN and DR, promote the recovery of renal function, and delay the disease progression through reducing the expression of serum VEGF, ACE and IGF-1.
Objective To explore the effect of sulodexide on serumvascular endothelial growth factor(VEGF), angiotensin converting enzyme(ACE) and insulin-like growth factor-1(IGF-1)levels in patients with diabetic nephropathy(DN)and diabetic retinopathy(DR). Methods 72 patients with DN and DR were randomly divided into study group(36 cases) and control group(36 cases). The control was given alprostadil, irbesartan and European bilberry anthocyanin/beta carotene, while the study group was given sequential therapy with sulodexide. The curative effects of DR in the two groups were compared, and the changes of urinary albumin excretion rate(UAER), serum VEGF, ACE and IGF-1 levels were observed before and after treatment. Results There was no significant difference in the curative effects of DR between the two groups(P>0.05). 16 weeks after treatment, the levels of UAER, VEGF, ACE and IGF-1 in the two groups were all significantly decreased, and the decrease in the study group was greater than that in the control group(P<0.05). Conclusion Sulodexide can effectively alleviate the fundus lesions in patients with DN and DR, promote the recovery of renal function, and delay the disease progression through reducing the expression of serum VEGF, ACE and IGF-1.
引文
[1]王蜀湘,胡延海.舒洛地特联合瑞格列奈治疗糖尿病肾病的临床研究[J].现代药物与临床,2016,31(4):475-478.
[2]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华糖尿病杂志,2014,8(7):447-498.
[3]文哲瑶,王琪,唐喜香,等.舒洛地特对高糖诱导的人视网膜微血管内皮细胞功能紊乱的作用及其机制[J].中山大学学报(医学科学版),2016,37(3):376-383.
[4]王彦,唐琳.舒洛地特注射液联合缬沙坦胶囊治疗糖尿病肾病的临床研究[J].中国临床药理学杂志,2016,32(21):1953-1956.
[5]高丹,吴歌,景三辉,等.舒洛地特治疗糖尿病肾病蛋白尿临床评价[J].中国药业,2017,26(16):65-67.
[6]段宇芬.利格列汀结合舒洛地特治疗对糖尿病肾病患者血管内皮细胞生长因子影响的研究[J].中国药物与临床,2016,16(3):388-390.
[2]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华糖尿病杂志,2014,8(7):447-498.
[3]文哲瑶,王琪,唐喜香,等.舒洛地特对高糖诱导的人视网膜微血管内皮细胞功能紊乱的作用及其机制[J].中山大学学报(医学科学版),2016,37(3):376-383.
[4]王彦,唐琳.舒洛地特注射液联合缬沙坦胶囊治疗糖尿病肾病的临床研究[J].中国临床药理学杂志,2016,32(21):1953-1956.
[5]高丹,吴歌,景三辉,等.舒洛地特治疗糖尿病肾病蛋白尿临床评价[J].中国药业,2017,26(16):65-67.
[6]段宇芬.利格列汀结合舒洛地特治疗对糖尿病肾病患者血管内皮细胞生长因子影响的研究[J].中国药物与临床,2016,16(3):388-390.